Immunotherapy for children with malignant brain tumors

封面

如何引用文章

全文:

详细

The incidence of high-grade malignant gliomas (MG) ranges from 35 to 46% of all central nervous system tumors. Despite combined therapy including surgery, radiation treatment and chemotherapy, overall five-year survival does not exceed 10%. The advent of novel immunotherapeutic strategies has promoted a renewed hopes for the treatment of MG. The aim of the present study was to improve the survival rates of glioma patients.

Our study included 5 pediatric patients at the median age of 7.6 years (2-16). Three pts had anaplastic astrocytoma (AA) (1st relapse, 1 pt; 2nd relapse, in 2 pts), One patient was diagnosed with glioblastoma multiforme (GBM) (3rd recurrence), and 1 child had diffuse brainstem glioma (BSG). The median time to the first relapse was 12 months (4 to 16), the second relapse occurred at a median of 5 months (1 to 8). The protocol of immunotherapy included combined administration of autologous dendritic cell-based vaccine (DV) and repeated intrathecal/intraventricular injections of donor allogeneic immunocompetent cells (alloIC) for at least 2 years.

Two of 3 pts with AA experienced a progression-free interval of 67 and 71 months. One patient with 3rd GBM relapse is alive without any treatment for 13.3 years after starting the immunotherapy. The median time of follow-up was 67 months, with the 2-year overall survival rate of 58%. Two pts died from the disease progression within 6 and 7 months from the beginning of immunotherapy. Over the period of treatment, the patients received a median of 20 alloIC injections (8 to 60), and 18 DV administrations (8 to 44). No serious side-effects were observed.

Immunotherapy could be an promising option for treating patients with high-grade malignant gliomas refractory to conventional therapy and, therefore, deserves further investigations.

作者简介

I. Dolgopolov

Tver State Medical University; Children’s Regional Clinical Hospital

Email: wordex2006@rambler.ru
ORCID iD: 0000-0001-9777-1220

PhD, MD (Medicine), Head, Department of Pediatrics, Pediatric Faculty, Deputy Chief Physician for Medical Work

俄罗斯联邦, Tver; Tver

M. Rykov

Russian State Social University

编辑信件的主要联系方式.
Email: wordex2006@rambler.ru
ORCID iD: 0000-0002-8398-7001

PhD, MD (Medicine), Associate Professor, Head, Department of Pediatrics

俄罗斯联邦, 4 Wilhelm Pieck St, Bldg 1 Moscow 129226

参考

  1. Чкадуа Г.З., Заботина Т.Н., Буркова A.A., Тамаева З.Э., Огородникова Е.В., Жорданиа К.И., Кадагидзе З.Г., Барышников А.Ю. Адаптирование методики культивирования дендритных клеток человека из моноцитов периферической крови для клинического применения // Российский биотерапевтический журнал, 2002. Т. 1, № 3. С. 56-59. [Chkadua G.Z., Zabotina T.N., Burkova A.A., Tamaeva Z.E., Ogorodnikova E.V., Jordania I., Kadagidze Z.G., Baryshnikov A.Yu. The adaptation of method of generating monocyte derived human dendritic cells for clinical practice. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy, 2002, Vol. 1, no. 3, pp. 56-59. (In Russ.)]
  2. Чкадуа Г.З., Борунова А.А., Шоуа И.Б., Долгополов И.С., Пименов Р.И., Михайлова И.Н., Заботина Т.Н., Барышникова М.А. Криоконсервация дендритных клеток человека для клинического применения // Российский биотерапевтический журнал, 2019. Т. 18, № 4. С. 65-75. [Chkadua G.Z., Borunova A.A., Shoua I.B., Dolgopolov I.S., Pimenov R.I., Mikhailova I.N., Zabotina T.N., Baryshnikova M.A. Cryo preservation of human dendritic cells for clinical USE. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy, 2019, Vol. 18, no. 4, pp. 65-75. (In Russ.)]
  3. Almuhaisen G., Alhalaseh Y., Mansour R., Abu-Shanab A., Al-Ghnimat S., Al-Hussaini M. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA). Brain Tumor Pathol., 2021, Vol. 38, no. 1, pp. 14-22.
  4. Ardon H., van Gool S.W., Verschuere T. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol. Immunother., 2012, Vol. 61, no. 11, pp. 2033-2044.
  5. Auffinger B., Thaci B., Nigam P., Rincon E., Cheng Y., Lesniak M. New therapeutic approaches for malignant glioma: in search of the Rosetta stone. F1000 Med. Rep., 2012, Vol. 4, 18. doi: 10.3410/M4-18.
  6. Chung D, Shin H, Hong Y. A New Hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J. Immunol. Res., 2014, Vol. 2014, 326545. doi: 10.1155/2014/326545.
  7. Cui Y., Tha K.K., Terasaka S., Yamaguchi S., Wang J., Kudo K. Prognostic Imaging Biomarkers in Glioblastoma: Development and Independent Validation on the Basis of Multiregion and Quantitative Analysis of MR Images. Radiology, 2016, Vol. 278, no. 2, pp. 546-553.
  8. Eagles M., Nassiri F., Badhiwala J., Suppiah S., Almenawer S., Zadeh G., Aldape K. Dendritic cell vaccines for high-grade gliomas. Ther. Clin. Risk Manag., 2018,Vol. 14, pp. 1299-1313.
  9. Ellingson B.M. Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. Curr. Neurol. Neurosci. Rep., 2015, Vol. 15, no. 1, 506. doi: 10.1007/s11910-014-0506-0.
  10. Frederico S.C., Hancock J.C., Brettschneider E.E.S., Ratnam N.M., Gilbert M.R., Terabe M. Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma. Front. Oncol., 2021, Vol. 11, 672508. doi: 10.3389/fonc.2021.672508.
  11. Han S.J., Zygourakis C., Lim M., Parsa A.T. Immunotherapy for glioma: promises and challenges. Neurosurg. Clin. N. Am., 2012, Vol. 23, no. 3, pp. 357-370.
  12. Hanif F., Muzaffar K., Perveen K., Malhi S.M., Simjee Sh.U. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac. J. Cancer Prev., 2017, Vol. 18, no. 1, pp. 3-9.
  13. Hayes R.L., Koslow M., Hiesiger E.M. Improved long-term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. J. Cancer, 1995, Vol. 76, no. 5, pp. 840-852.
  14. Jacobs S.K., Wilson D.J., Kornblith P.L., Grimm E.A. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res., 1986, Vol. 46, pp. 2101-2104.
  15. Jordan J.T., Sun W., Hussain S.F., DeAngulo G., Prabhu S.S., Heimberger A.B. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother., 2008, Vol. 57, no. 1, pp. 123-131.
  16. Kang X., Zheng Y., Hong W., Chen X., Li H., Huang B., Huang Z., Tang H., Geng W. Recent advances in immune cell therapy for glioblastoma. Front. Immunol., 2020, Vol. 11, 544563. doi: 10.3389/fimmu.2020.544563.
  17. Kitahara T., Watanabe O., Yamaura A., Makino H., Watanabe T., Suzuki G., Okumura K. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J. Neurooncol., 1987, Vol. 4, no. 4, pp. 329-336.
  18. Kmiecik J., Zimmer J., Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J. Neurooncol., 2014, Vol. 116, pp. 1-9.
  19. Liau L.M., Ashkan K., Tran D.D., Campian J.L., Trusheim J.E., Cobbs C.S. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J. Transl. Med., 2018, Vol. 16, no. 1, 142. doi: 10.1186/s12967-018-1507-6.
  20. Lillehei K.O., Mitchell D.H., Johnson S.D., McCleary E.L., Kruse C.A. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery, 1991, Vol. 28, no. 1, pp. 16-23.
  21. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol., 2016, Vol. 131, no. 6, pp. 803-820.
  22. Meuleman N., Ahmad I., Duvillier H. Intrathecal donor lymphocyte infusion for the treatment of suspected refractory lymphomatous meningitis: a case report. Eur. J. Haematol., 2006, Vol. 77, pp. 523-526.
  23. Neumann M., Blaw I.W., Burmeister T. Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation. Ann. Hematol., 2011, Vol. 90, no. 8, pp. 911-916.
  24. Ostrom Q.T., Cioffi G., Gittleman H., Patil N., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol., 2019, Vol. 21, Suppl, 5, pp. v1-v100.
  25. Pellegatta S., Eoli M., Cuccarini V., Anghileri E., Pollo B., Pessina S. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide. Oncoimmunology. 2018, Vol. 7, no. 4, e1412901. doi: 10.1080/2162402X.2017.1412901.
  26. Poon С., Sarkar S., Yong V., Kelly J. Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. Brain, 2017, Vol. 140, no. 6, pp. 1548-1560.
  27. Quattrocchi K.B., Miller C.H., Cush S. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol., 1999, Vol. 45, no. 2, pp. 141-157.
  28. Rolle C., Sengupta S., Lesniak M. Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurg. Clin. N. Am., 2010, Vol. 21, no. 1, pp. 201-214.
  29. Ruggeri L., Capanni M., Urbani F. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 2002, Vol. 295, pp. 2097-2100.
  30. Stummer W., Reulen H.J., Meinel T., Pichlmeier U., Schumacher W., Tonn J.C. ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 2008, Vol. 62, no. 3, pp. 564-576; discussion 564-576.
  31. Stupp R., Mason W.P., van den Bent M.J. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, Vol. 352, pp. 987-996.
  32. Thakkar J.P., Dolecek T.A., Horbinski C., Ostrom Q.T., Lightner D.D., Barnholtz-Sloan J.S., Villano J.L. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomarkers Prev., 2014, Vol. 23, no. 10, pp. 1985-1996.
  33. Vik-Mo E.O., Nyakas M., Mikkelsen B.V., Moe M.C., Due-Tønnesen P., Suso E.M. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol. Immunother., 2013, Vol. 62, no. 9, pp. 1499-1509.
  34. Wheeler C.J., Black K.L., Liu G., Mazer M., Zhang X.X., Pepkowitz S. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res., 2008, Vol. 68, no. 14, pp. 5955-5964.
  35. Willem C., Makanga D.R., Guillaume T., Maniangou B., Legrand N., Gagne K. Impact of KIR/HLA incompatibilities on NK cell reconstitution and clinical outcome after T cell-replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide. J. Immunol., 2019, Vol. 202, no. 7, pp. 2141-2152.
  36. Witthayanuwat S., Pesee M., Supaadirek C., Supakalin N., Thamronganantasakul K., Krusun S. Survival analysis of glioblastoma multiforme. Asian Pac. J. Cancer Prev., 2018, Vol. 19, no. 9, pp. 2613-2617.
  37. Yamanaka R., Homma J., Yajima N., Tsuchiya N., Sano M., Kobayashi T. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. Clin. Cancer Res., 2005, Vol. 11, pp. 4160-4167.
  38. Zagzag D., Salnikow K., Chiriboga L., Yee H., Lan L., Ali M.A. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab. Invest., 2005, Vol. 85, no. 3, pp. 328-341.
  39. Zakerinia M., Kamgarpour A., Nemati H., Zare H., Ghasemfar M., Rezvani A., Karimi M. Intrathecal autologous bone marrow-derived hematopoietic stem cell therapy in neurological diseases. Int. J. Organ Transplant. Med., 2018, Vol. 9, no. 4, pp. 157-167.

补充文件

附件文件
动作
1. JATS XML
下载
2. Figure 1. Overall two-year survival in patients with gliomas

下载 (93KB)
索引源数据

版权所有 © Долгополов И., Рыков М., 2024

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##